Yariswamy Manjunath

Yariswamy Manjunath

Auto-generated profile, based on publicly available information

Yariswamy Manjunath

Department of Surgery, Ellis Fischel Cancer Center, Roy Blunt NextGen Precision Health Institute, University of Missouri, Columbia, Missouri. 1

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
Kanve N. SuvileshKanve N. Suvilesh
Kanve N. Suvilesh
YMYariswamy Manjunath
Yariswamy Manjunath
YNYulia Nussbaum
Yulia Nussbaum
MGMohamed Gadelkarim
Mohamed Gadelkarim
MRMurugesan Raju
Murugesan Raju
Jussuf KaifiJussuf Kaifi
Jussuf Kaifi
Purpose: Systemic treatments given to patients with non–small cell lung cancer (NSCLC) are often ineffective due to drug resistance. In the present study, we investigated patient-derived tumor organoids (PDTO) and matched tumor tissues from surgically treated patients with NSCLC to identify drug repurposing targets to overcome resistance toward standard-of-care platinum-based doublet chemotherapy. Experimental Design: PDTOs were established from 10 prospectively enrolled patients with non-metastatic NSCLC from resected tumors. PDTOs were compared with matched tumor tissues by histopathology/immunohistochemistry, whole exome sequencing, and transcriptome sequencing. PDTO growths and drug responses were determined by measuring 3D tumoroid volumes, cell viability, and proliferation/apoptosis. Differential gene expression analysis identified drug-repurposing targets. Validations were performed with internal/external data sets of patients with NSCLC. NSCLC cell lines were used for aldo-keto reductase 1B10 (AKR1B10) knockdown studies and xenograft models to determine the intratumoral bioavailability of epalrestat. Results: PDTOs retained histomorphology and pathological biomarker expression, mutational/transcriptomic signatures, and cellular heterogeneity of the matched tumor tissues. Five (50%) PDTOs were chemoresistant toward carboplatin/paclitaxel. Chemoresistant PDTOs and matched tumor tissues demonstrated overexpression of AKR1B10. Epalrestat, an orally available AKR1B10 inhibitor in clinical use for diabetic polyneuropathy, was repurposed to overcome chemoresistance of PDTOs. In vivo efficacy of epalrestat to overcome drug resistance corresponded to intratumoral epalrestat levels. Conclusions: PDTOs are efficient preclinical models recapitulating the tumor characteristics and are suitable for drug testing. AKR1B10 can be targeted by repurposing epalrestat to overcome chemoresistance in NSCLC. Epalrestat has the potential to advance to clinical trials in patients with drug-resistant NSCLC due to favorable toxicity, pharmacological profile, and bioavailability.

1 September 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MYManjunath Yariswamy
Manjunath Yariswamy
TYTadashi Yoshida
Tadashi Yoshida
AVAnthony J. Valente
Anthony J. Valente
HKHemanth Kumar Kandikattu
Hemanth Kumar Kandikattu
SSSiva S.V.P. Sakamuri
Siva S.V.P. Sakamuri
BCBysani Chandrasekar
Bysani Chandrasekar
TRAF3IP2 (TRAF3 interacting protein 2; previously known as CIKS or Act1) is a key intermediate in the normal inflammatory response and the pathogenesis of various autoimmune and inflammatory diseases. Induction of TRAF3IP2 activates IκB kinase (IKK)/NF-κB, JNK/AP-1, and c/EBPβ and stimulates the expression of various inflammatory mediators with negative myocardial inotropic effects. To investigate the role of TRAF3IP2 in heart disease, we generated a transgenic mouse model with cardiomyocyte-specific TRAF3IP2 overexpression (TRAF3IP2-Tg). Echocardiography, magnetic resonance imaging, and pressure-volume conductance catheterization revealed impaired cardiac function in 2-month-old male transgenic (Tg) mice as evidenced by decreased ejection fraction, stroke volume, cardiac output, and peak ejection rate. Moreover, the male Tg mice spontaneously developed myocardial hypertrophy (increased heart/body weight ratio, cardiomyocyte cross-sectional area, GATA4 induction, and fetal gene re-expression). Furthermore, TRAF3IP2 overexpression resulted in the activation of IKK/NF-κB, JNK/AP-1, c/EBPβ, and p38 MAPK and induction of proinflammatory cytokines, chemokines, and extracellular matrix proteins in the heart. Although myocardial hypertrophy decreased with age, cardiac fibrosis (increased number of myofibroblasts and enhanced expression and deposition of fibrillar collagens) increased progressively. Despite these adverse changes, TRAF3IP2 overexpression did not result in cell death at any time period. Interestingly, despite increased mRNA expression, TRAF3IP2 protein levels and activation of its downstream signaling intermediates remained unchanged in the hearts of female Tg mice. The female Tg mice also failed to develop myocardial hypertrophy. In summary, these results demonstrate that overexpression of TRAF3IP2 in male mice is sufficient to induce myocardial hypertrophy, cardiac fibrosis, and contractile dysfunction.

3 September 2024
Verified
Other
Open access
PDF file
Kanve N. SuvileshKanve N. Suvilesh
Kanve N. Suvilesh
YMYariswamy Manjunath
Yariswamy Manjunath
YNYulia Nussbaum
Yulia Nussbaum
MGMohamed Gadelkarim
Mohamed Gadelkarim
MRMurugesan Raju
Murugesan Raju
Jussuf KaifiJussuf Kaifi
Jussuf Kaifi
Supplementary Figure S1. Development and histomorphological characterization of patient-derived tumor organoid (PDTO) models.

3 September 2024
Verified
Other
Open access
PDF file
Kanve N. SuvileshKanve N. Suvilesh
Kanve N. Suvilesh
YMYariswamy Manjunath
Yariswamy Manjunath
YNYulia Nussbaum
Yulia Nussbaum
MGMohamed Gadelkarim
Mohamed Gadelkarim
MRMurugesan Raju
Murugesan Raju
Jussuf KaifiJussuf Kaifi
Jussuf Kaifi
Supplementary Figure S3. Gene expression comparison between matched patient-derived tumor organoids (PDTOs) and patient primary tumors (PT) by whole transcriptome analysis.

3 September 2024
Verified
Other
Open access
PDF file
Kanve N. SuvileshKanve N. Suvilesh
Kanve N. Suvilesh
YMYariswamy Manjunath
Yariswamy Manjunath
YNYulia Nussbaum
Yulia Nussbaum
MGMohamed Gadelkarim
Mohamed Gadelkarim
MRMurugesan Raju
Murugesan Raju
Jussuf KaifiJussuf Kaifi
Jussuf Kaifi
Supplementary Figure S13. Dose titration of commonly used cytotoxic agents against LUAC (n = 6) and LUSC (n = 6) cell lines.

3 September 2024
Verified
Other
Open access
Kanve N. SuvileshKanve N. Suvilesh
Kanve N. Suvilesh
YMYariswamy Manjunath
Yariswamy Manjunath
YNYulia Nussbaum
Yulia Nussbaum
MGMohamed Gadelkarim
Mohamed Gadelkarim
MRMurugesan Raju
Murugesan Raju
Jussuf KaifiJussuf Kaifi
Jussuf Kaifi
Supplementary File S1. Somatic single nucleotide polymorphic (SNP) mutations identified in PDTOs and matched patient tumors.